BMS’ big merger bet is still on with latest CAR-T filingBristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final Share XBMS’ big merger bet is still on with latest CAR-T filinghttps://pharmaphorum.com/news/bms-and-bluebird-file-multiple-myeloma-car-t/
Takeda’s Ninlaro falls short in first line multiple myelomaTakeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid Share XTakeda’s Ninlaro falls short in first line multiple myelomahttps://pharmaphorum.com/news/takedas-ninlaro-falls-short-in-first-line-multiple-myeloma/
BMS/AbbVie’s combo falls short in untreated multiple myeloma trialAdding Bristol-Myers Squibb/AbbVie’s Empliciti to Revlimid, developed by BMS’ recently acquired Celgene unit, does not improve survival in Share XBMS/AbbVie’s combo falls short in untreated multiple myeloma trialhttps://pharmaphorum.com/news/bms-abbvies-combo-falls-short-in-untreated-multiple-myeloma-trial/
Sanofi gets first OK for isatuximab for myeloma, challenging J&J’s DarzalexSanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming Share XSanofi gets first OK for isatuximab for myeloma, challenging J&J’s Darzalexhttps://pharmaphorum.com/news/sanofi-gets-first-ok-for-isatuximab-for-myeloma-challenging-jjs-darzalex/
Janssen’s Darzalex approved in EU for newly-diagnosed multiple myelomaJanssen’s Darzalex (daratumumab) has been approved in Europe as a combination therapy in newly-diagnosed patients with multiple myeloma. Share XJanssen’s Darzalex approved in EU for newly-diagnosed multiple myelomahttps://pharmaphorum.com/news/janssens-darzalex-approved-in-eu-for-multiple-myeloma/
Life with multiple myelomaMultiple myeloma patient Bob Munro (pictured below) explains what it’s like to live with the rare blood cancer and Share XLife with multiple myelomahttps://pharmaphorum.com/partner-content/life-with-multiple-myeloma/
GSK files multiple myeloma drug with FDA after phase 2 successGSK has filed for FDA approval of its potential first-in-class multiple myeloma drug belantamab mafodotin for relapsed/refractory multiple Share XGSK files multiple myeloma drug with FDA after phase 2 successhttps://pharmaphorum.com/news/gsk-files-multiple-myeloma-drug-with-fda-after-phase-2-success/
J&J gets okay for a third first-line Darzalex combo in USJohnson & Johnson continues to extend the use of its Darzalex therapy in newly-diagnosed multiple myeloma patients, getting Share XJ&J gets okay for a third first-line Darzalex combo in UShttps://pharmaphorum.com/news/jj-gets-okay-for-a-third-first-line-darzalex-combo-in-us/
GSK scores major trial win with potential multiple myeloma blockbusterGlaxoSmithKline may have scored a major cancer trial win after its belantamab mafodotin hit targets in the pivotal Share XGSK scores major trial win with potential multiple myeloma blockbusterhttps://pharmaphorum.com/news/gsk-scores-major-trial-win-with-potential-multiple-myeloma-blockbuster/
